12:00 AM
Dec 12, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Promacta regulatory update

FDA removed restricted distribution and data collection requirements from the REMS for 2 chronic idiopathic thrombocytopenic purpura (ITP) drugs - Promacta eltrombopag and Nplate romiplostim - after concluding the programs were not necessary to evaluate long-term safety. The agency said safety data collected by healthcare professionals were confounded by ITP patients' underlying...

Read the full 248 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >